Bridgebio Pharma Inc
About
Bridgebio Pharma Inc (NASDAQ:BBIO) — investor relations, events, news, and company updates on 6ix.
Latest News
Apr 22 2026
BBOT Announces the Appointment of Pedro J. Beltran, PhD, as Chief Executive Officer, Idan Elmelech as Chief Operating Officer, and Neil Kumar, PhD, as Executive Chairman
Mar 30 2026
Acoramidis Significantly Reduces the Risk of All-Cause and Cardiovascular Mortality in Patients with ATTR-CM through Month 54
Mar 30 2026
BridgeBio Submits NDA to FDA for BBP-418 for Individuals Living with LGMD2I/R9
Mar 23 2026
BridgeBio to Present Long-Term Efficacy and Safety Data from the ATTRibute-CM OLE Trial at the ACC Annual Scientific Sessions
Mar 11 2026
BBP-418 Demonstrates Consistent Efficacy and Favorable Safety Profile in Phase 3 FORTIFY Interim Analysis in LGMD2I/R9
Recent Videos
In a new Off-Target Effects with Matt Gline, Matt will speak with BridgeBio CEO Neil Kumar.
Apr 22, 2026
Why most new medicines fail and a model built to beat the odds
Apr 16, 2026
How to Invest in Bridgebio Pharma Inc (BBIO) Step by Step
Apr 12, 2026
Support for Your Patients Throughout the Attruby® (acoramidis) Treatment Journey
Mar 13, 2026
Financials
Revenue
$502.08 M
Market Cap
$14.18 B
EPS
-3.78